Phase 4 Parkinson's Disease Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been clinically diagnosed with Parkinson's disease, diffuse Lewy body disease, multiple systems atrophy, Huntington's Disease, Frontotemporal Dementia, or a related condition (patient group)
- People who are healthy and are matched by age and gender to someone in the patient group (healthy comparison group)
- People in the patient group who have experienced hallucinations or delusions that started after their neurological diagnosis, happen at least once a week for four weeks, and are severe enough that a doctor considers treatment necessary
- People who have a study partner (such as a family member or carer) who is able to attend study visits with them
Who may not be able to join:
- People who have had a stroke in the past, or who have another serious neurological or medical condition that is not well controlled
- People who are unable to have an MRI scan, or for whom an MRI scan would be medically unsafe
- People who have taken serotonin-related medications within the last six weeks
- People who are not able to give their own independent consent to take part
- People who are pregnant or breastfeeding
- People whose hallucinations or delusions are caused by a metabolic condition, toxic substance, or a primary psychiatric illness (rather than their neurological diagnosis)
- People who a doctor considers unlikely to be able to complete the thinking and memory tests involved in the study
- People with Parkinson's disease who are currently taking, or have previously taken, the medication pimavanserin
- People who have taken antipsychotic medications within the last two weeks
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Ciaran Considine, PhD, Vanderbilt University Medical Center
Phone: 6154210569
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in 5HT2A receptor density measured using the PET radioligand MH.MZ; Change in 5HT2A receptor binding occupancy measured using the PET radioligand MH.MZ
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.